on May 16, 2023, Amy Broidrick, President, Chief Strategy and Operating Officer and a director of Qualigen Therapeutics, Inc., provided her resignation to the company, which became effective June 16, 2023 (the Separation Date). Ms. Broidrick's departure was not related to any disagreement with the company on any matter relating to the company's operations, policies, or practices. Effective as of the Separation Date, Ms. Broidrick also resigned from all officer and director positions with the company and its subsidiaries.